A central laboratory is a laboratory commissioned for a clinical trial that analyzes samples from multiple trial sites according to uniform requirements. It supports the comparability of laboratory values through standardized methods, processes, and data transmission. Its role ranges from sample logistics and analysis to the controlled provision of results.
Role in multicenter trials
In a multicenter study, blood, urine, tissue, or other samples may be sent to a central laboratory. The analysis is performed there according to defined methods and procedures. This helps limit differences that could arise if multiple laboratories used different equipment, reagents, units, or reference ranges. This is particularly important when laboratory values are intended as inclusion or exclusion criteria, safety parameters, or efficacy variables.
The central laboratory operates on the basis of the protocol, the laboratory agreement, and detailed instructions. These specify which samples are to be collected, when and how they are to be collected, processed, stored, transported, and analyzed. They also define reporting pathways, the handling of repeat analyses, critical results, and deviations. The EU-GCP inspection guideline for clinical laboratories considers, among other aspects, quality assurance, standard operating procedures, personnel qualifications, data archiving, and availability for monitoring, audits, and inspections.
Standardization, reference ranges, and data
Uniform analytics alone are not sufficient. Laboratory results must be transmitted with the method, unit, reference range, date, and sample status in a way that makes their clinical and statistical interpretation traceable. The reference range of a central laboratory is therefore part of the data interpretation; it must not be inadvertently mixed with local ranges. In the event of methodological changes or new reference ranges, the effects on ongoing analyses must be assessed and documented.
ISO 15189:2022 describes requirements for the quality and competence of medical laboratories. For clinical trials, the standard replaces neither the protocol nor GCP requirements. However, it can support a quality management system, while the laboratory’s suitability must always be assessed for the intended use in the study. Electronic laboratory transfers require defined interfaces, verification steps, and traceability so that results can be correctly assigned to the right visit and person.
Sample logistics begin before collection. The central laboratory can provide preconfigured sample collection kits with suitable containers, labels, instructions, packaging, and shipping documents. They are intended to make the conditions required by the protocol for collection, processing, and transport practically implementable at the trial site. Shipping routes, temperature requirements, pickup times, and the handling of unsuitable samples must be described in advance.
Upon receipt at the central laboratory, identity, condition, and, where applicable, deviations are checked. Samples that are inadequately labeled, damaged, or transported outside the specified conditions may have impaired usability. The laboratory therefore needs procedures for receipt inspection, inquiries, documented decisions, and communication of critical values. These processes contribute to data integrity and, where applicable, timely medical care.
Study planning also requires a realistic assessment of geographical reach and turnaround times. Long transportation routes or public holidays may affect preanalytics and feedback. The selected processes should therefore be justifiably based on the actual sample profile, stability, and intended clinical decisions.
Distinction from the local trial site laboratory
A local trial site laboratory operates at or near the trial site and may generate findings required for immediate clinical care or time-critical decisions. It does not automatically use the same methods or reference ranges as a central laboratory. A local value may therefore be decisive for care without being considered a central study value unless otherwise specified.
The central laboratory primarily serves cross-study standardization. Both types of laboratory may be provided for in a study in parallel. The protocol must then clearly specify which value is to be used for eligibility, dosing decisions, safety assessment, data analysis, or medical treatment. This distinction prevents contradictory documentation and unclear data flows.
Relevance for clinical trials
A central laboratory links sample quality with the comparability of the data derived from samples. Operational risks frequently arise from incorrect labeling, unclear time windows, inadequate temperature control, missing results, and uncoordinated reference ranges. Robust planning therefore aligns the laboratory manual, kit logistics, data transmission, and communication pathways with the protocol.
Full-service CROs such as Mediconomics support the selection and management of central laboratories, the coordination of laboratory agreements and laboratory manuals, and the coordination of kit shipment and sample logistics. They monitor interfaces with trial sites and data management, track deviations, and support the preparation of monitoring, audits, and inspections.
Frequently Asked Questions (FAQ)
Does a central laboratory replace the local laboratory?
Not necessarily. Local laboratories may be required for time-critical care, while the central laboratory performs standardized study analyses.
Why are reference ranges important?
They determine how a value is interpreted. For analysis and assessment, it must be clear which laboratory and which range apply.
What happens when a sample is unsuitable?
The further procedure is governed by the laboratory manual and protocol. Acceptance, rejection, repetition, and communication must be documented.
Regulatory references
- EudraLex Volume 10, Annex II on clinical laboratories – inspection aspects for laboratories handling study samples.
- ISO 15189:2022 – requirements for the quality and competence of medical laboratories.
- ICH E6(R3) Good Clinical Practice – data integrity, documentation, and sponsor responsibility.
- Regulation (EU) No 536/2014 – protection of participants and reliable study data.